Overview

Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

Status:
Recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

This research study is assessing a new drug, duvelisib, in combination with a drug that is already FDA approved, venetoclax, as a possible treatment for participants with CLL or those with Richter's Syndrome

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborators:

Secura Bio, Inc.
Verastem, Inc.

Treatments:

Venetoclax